21st Century Business Herald Ji Yuanyuan Intern Reporter Li Jiaying Reported from Shanghai
The 7th China International Import Expo (referred to as "CIIE") was held as scheduled in Shanghai from November 5th to 10th. GSK brought multiple innovative products and highlight activities to the CIIE.
The CIIE is not only a window for building a new development pattern, but also a platform for promoting high-level openness and a globally shared international public good. Benefiting from the spillover effects of the CIIE, GSK has accelerated the landing of multiple vaccine products in China. Among them, the recombinant herpes zoster vaccine Xinanlisi and the imported bivalent human papillomavirus (HPV) vaccine Xiruishi have successfully achieved commercialization in China.
During the CIIE, GSK not only brought innovation driven vaccine products, but also actively participated in public health forums, held a roundtable forum on "Deepening the Integration of Medical and Preventive Medicine and Building a Healthy China", and explored the integration model of medical and preventive medicine with multiple parties to jointly promote the modernization of China's disease control system. At the same time, GSK actively advocates and practices the implementation of vaccine prescription pilot work, aiming to enhance the accessibility of innovative products and benefit more patients.
GSK Vice President and Head of China Vaccine Business, Li Weidong, told 21st Century Business Herald reporters that GSK is committed to "based in China, working together with China, and serving China", focusing on innovation core, and continuously deepening the Chinese market with local partners to enhance vaccine accessibility. In the future, GSK will continue to promote vaccine innovation, assist in the implementation and landing of innovative vaccine prescription models, and put "medical prevention integration and prevention first" into practice, continuously bringing more positive health impact to the Chinese public and contributing to the promotion of the Healthy China initiative.
Going to CIIE again: GSK vaccine sector leads innovation trend
As an important platform for China's opening up to the outside world, the CIIE plays a driving role in accelerating the introduction, approval, and listing of innovative products.
Li Weidong introduced that high-quality products are like a thousand mile horse, while the CIIE is like a discerning Bo Le, providing a valuable showcase for innovative products. At present, GSK has developed a rich product line covering all age groups from children to adults, committed to providing full lifecycle health protection for 2.5 billion people worldwide. At this year's CIIE, the GSK booth will consist of four parts: "Strategic Pipeline and Research and Development", "Vaccines", "Respiratory", and "Special Drugs".
At this year's CIIE, GSK not only brings innovation driven vaccine products, but also reflects a profound understanding and precise layout of the Chinese market. Among them, the recombinant herpes zoster vaccine Xinanlisi has won the "Nobel Prize" in the pharmaceutical industry three times - the Prix Galien Award. Xin'an Lishi has effectively filled the gap in China's prevention of herpes zoster disease and further enriched China's vaccine prevention system. Benefiting from the spillover effect of the CIIE, Xin'an Lishi quickly completed its commercial landing in China, which is of great significance for reducing the incidence of herpes zoster, improving the health level and quality of life of the elderly, and promoting healthy aging.
Another imported bivalent HPV vaccine, Xiruishi, also comes from a prestigious family and is currently the only HPV vaccine that uses an innovative adjuvant system. This innovative adjuvant system embodies the research achievements of the 2011 Nobel Prize in Physiology or Medicine, putting prevention first into practice and helping to promote China's action and goal of eliminating cervical cancer as soon as possible.
At the technical level, GSK has been deeply involved in adjuvant research and development for many years, and multiple products have adopted innovative adjuvants.
Adjuvants, as an effective enhancer, can significantly enhance the immune response level of vaccines. Adding adjuvants to vaccines is of great significance for responding to disease pandemics or emergency prevention. Adjuvants can reduce the amount of antigen required for each dose of vaccine, thereby increasing vaccine production capacity and protecting more people from disease.
From the perspective of vaccine research and development system, GSK has 1/4 of its global R&D pipeline focused on the vaccine field. Currently, there are over 20 candidate vaccines in the R&D and registration stages, covering multiple important fields such as respiratory syncytial virus vaccine, meningococcal vaccine, pneumococcal vaccine, etc., committed to providing solid protection for human health throughout the entire life cycle Li Weidong further pointed out.
At present, GSK vaccines have multiple research and development centers in countries such as the United States and Belgium. Li Weidong stated that China is the world's second largest pharmaceutical market, and GSK will strive to keep up with the global research and development speed, shorten the time, and introduce the world's most innovative products to China as soon as possible. In addition, GSK also hopes to introduce overseas resources to serve the Chinese market, targeting the needs of the Chinese market and introducing excellent innovative products to benefit more patients.
Promoting vaccine prescriptions: improving vaccine accessibility
To truly benefit the public, in addition to continuously launching high-quality innovative products, it is also necessary to consider how to help promote the innovative development of China's medical and preventive integration system.
The "Healthy China 2030" plan outline and the construction of the national vaccine prevention emergency system after the epidemic have highlighted the importance of disease prevention. However, compared to the high coverage and public awareness of childhood vaccination, China's adult vaccination work appears relatively lagging behind. At the same time, China is facing dual challenges of aging population and chronic diseases.
According to data disclosed by the Chinese Center for Disease Control and Prevention, approximately 190 million elderly people in China suffer from chronic diseases. With the growth of age, the immune function of the middle-aged and elderly people decreases, their ability to resist disease invasion is low, and they often have chronic diseases at the same time. The risk of suffering from infectious diseases (such as influenza, pneumonia, herpes zoster) increases, and their health status is not optimistic.
In this context, the demand for vaccine prescriptions is gradually being seen. It is understood that vaccine prescription is a prescription issued by general practitioners or other medical professionals during clinical diagnosis and treatment, used to recommend or guide patients to receive specific vaccines. This prescription is different from traditional vaccination methods, as it focuses more on providing personalized vaccination recommendations based on the patient's actual health condition and needs.
As an important means to enhance the popularization and accessibility of vaccines, the significance of vaccine prescription lies in closely integrating vaccines with the diagnosis and treatment process of clinical doctors, providing patients with more accurate and convenient vaccination services.
At present, Shanghai, Guangdong, Hubei, Zhejiang, Shandong, Chongqing and other places are actively exploring "trial water" vaccine prescriptions, and have successively launched pilot work of "vaccine prescriptions/health prescriptions issued by general practitioners". GSK is also actively responding to the call, deeply participating in relevant projects and providing platform support.
GSK has demonstrated a forward-looking strategic vision and firm execution in promoting vaccine prescriptions. Li Weidong emphasized that promoting vaccine prescriptions is key to further developing the Chinese vaccine market.
"For example, when a patient goes to the respiratory department for medical treatment, the clinician suggests that the patient be vaccinated with influenza vaccine, pneumococcal vaccine, and herpes zoster vaccine because the patient has low immunity and is prone to suffer from related infectious diseases. In the past, most general hospitals and general hospitals did not have vaccination sites, so the patient could not go to the vaccination site in time, which may lead to vaccination hesitation after leaving the hospital. Therefore, the clinician can give the patient corresponding medical advice through the vaccine prescription, and the patient can also use this to go to the community hospital for vaccination, to improve the accessibility and convenience of the vaccine." Li Weidong said that promoting the vaccine prescription has a positive role in improving the accessibility and convenience of the vaccine.
As one of the first companies to pay attention to and implement vaccine prescription policies, GSK is actively promoting the deepening and implementation of the vaccine prescription system at multiple levels, aiming to enhance public awareness of the importance of vaccine prescriptions.
Promoting the integration of medical and preventive measures: achieving top-down vaccine management
To truly promote the implementation of vaccine prescriptions in China, we need to start from the source and achieve the integration of medical and preventive measures. Integrating vaccine prescriptions with prevention systems, building a top-down vaccine prevention and vaccination system, and completing the full chain management of vaccines from research and development to vaccination.
The construction of this vaccine prevention and vaccination system is not only closely linked to the demand of the Chinese vaccine market, but also achieves a win-win situation for all parties.
In Li Weidong's view, it is particularly crucial to work together with multiple parties to help build a three-dimensional or three-dimensional disease prevention system. The top-down vaccination system can effectively improve the convenience and accessibility of vaccination in China. Specifically, the system can cover the importance of communication and popularization of disease prevention between doctors and patients in general hospitals, doctors recommending vaccination based on patient conditions, doctors prescribing vaccines, and patients presenting prescriptions to outpatient clinics for vaccination.
On the one hand, for patients, they can obtain more convenient and precise vaccination services; For medical institutions, they can better fulfill their responsibilities in disease prevention; For the entire society, this has built a more solid and effective public health barrier. Li Weidong further pointed out that the integration of medicine and prevention means a comprehensive treatment concept throughout the entire life cycle. By continuously strengthening communication and exploration between patients and clinical doctors, we can truly bridge the "last mile" of disease prevention.
GSK has taken the lead in promoting the integration of medical and preventive measures. Since the beginning of this year, GSK has actively responded to the call of the "Healthy China Action" to "focus on prevention and combine prevention and treatment", combined with innovative models of medical and preventive integration in various regions, actively promoted disease and vaccine science education, and further promoted vaccine innovation accessibility on the basis of enhancing vaccine awareness.
GSK is actively involved in the integration of medical and preventive measures at different levels. We hope to contribute to the true realization of medical and preventive integration through vaccine prescriptions and communicate and explore with all parties, helping to improve the widespread accessibility of Chinese vaccines. In addition to promoting external projects, we also take the lead in implementing important measures of medical and preventive integration within the company. For example, all business units of GSK China work together to support and promote the advocacy of disease prevention and vaccination recommendations by specialized and general practitioners in comprehensive hospitals Li Weidong emphasized that GSK is not only an advocate of the concept of medical prevention integration, but also a firm practitioner of this concept.
At this CIIE, GSK deeply participated in the Public Health Forum and held a roundtable forum on "Deepening the Integration of Medicine and Prevention, Building a Healthy China Together". GSK discussed the integration model of medicine and prevention with academic associations and government agencies, promoted the modernization of China's disease control system, actively advocated and implemented the pilot work of vaccine treatment, improved the accessibility of innovative products, and helped more patients benefit early.